Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
75,239 questions in 5,342 reviews
current versionsNo studies 15,213 · 20.2%Ungraded 10,323 · 13.7%Very low 17,528 · 23.3%Low 17,951 · 23.9%Moderate 11,190 · 14.9%High 3,034 · 4%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Intervention NR Cognitive development · Preschool children from socially disadvantaged families Home‐based child development interventions for preschool children from socially disadvantaged families (2011) · Cochrane | no estimate extracted | 4 studies · 285 participants | Very low |
Intervention NR Socioemotional development · Preschool children from socially disadvantaged families Home‐based child development interventions for preschool children from socially disadvantaged families (2011) · Cochrane | no estimate extracted | 3 studies · 260 participants | Ungraded |
Intervention NR Adverse effects · Preschool children from socially disadvantaged families Home‐based child development interventions for preschool children from socially disadvantaged families (2011) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
workplace interventions vs no intervention Current pain at 10/12 months · patients with neck pain Workplace interventions for neck pain in workers (2011) · Cochrane | no estimate extracted | 2 studies · 267 participants | Low |
Roxithromycin vs placebo Patient response score Scale from: 1 to 6 · chronic rhinosinusitis in adults Systemic antibiotics for chronic rhinosinusitis without nasal polyps in adults (2011) · Cochrane | no estimate extracted | 1 study · 64 participants | Low |
Roxithromycin vs placebo Mean change from baseline of SNOT‐20 at the end of treatment Scale from: 0 to 5 · chronic rhinosinusitis in adults Systemic antibiotics for chronic rhinosinusitis without nasal polyps in adults (2011) · Cochrane | no estimate extracted | 1 study · 64 participants | Low |
Roxithromycin vs placebo Mean change from baseline of SNOT‐20 at 3 months post‐treatment Scale from: 0 to 5 · chronic rhinosinusitis in adults Systemic antibiotics for chronic rhinosinusitis without nasal polyps in adults (2011) · Cochrane | no estimate extracted | 1 study · 64 participants | Low |
Intervention NR Knowledge and understanding of cancer/treatment Patients and relatives · patients and carers Information interventions for orienting patients and their carers to cancer care facilities (2011) · Cochrane | no estimate extracted | 2 studies · 156 participants | Very low |
Intervention NR Trait anxiety STAI (T). Scale from: 0 to 60. Patients · patients and carers Information interventions for orienting patients and their carers to cancer care facilities (2011) · Cochrane | no estimate extracted | 1 study · 110 participants | Low |
Intervention NR State anxiety STAI‐S. Scale from: 0 to 60. Patients · patients and carers Information interventions for orienting patients and their carers to cancer care facilities (2011) · Cochrane | no estimate extracted | 2 studies · 188 participants | Low |
Intervention NR Distress POMS‐TMDS (unclear range of scores) Patients · patients and carers Information interventions for orienting patients and their carers to cancer care facilities (2011) · Cochrane | no estimate extracted | 2 studies · 188 participants | Low |
Intervention NR Depression BSI Patients · patients and carers Information interventions for orienting patients and their carers to cancer care facilities (2011) · Cochrane | no estimate extracted | 3 studies · 304 participants | Low |
Intervention NR Satisfaction by patients and relatives · patients and carers Information interventions for orienting patients and their carers to cancer care facilities (2011) · Cochrane | no estimate extracted | 1 study · 85 participants | Low |
Intervention NR Harms or adverse events ‐ not reported · patients and carers Information interventions for orienting patients and their carers to cancer care facilities (2011) · Cochrane | no estimate extracted | NR | No studies |
Xuezhikang vs simvastatin Cardiovascular events ‐ not reported · patients with hypercholesterolemia Chinese herbal medicines for hypercholesterolemia (2011) · Cochrane | no estimate extracted | NR | No studies |
Xuezhikang vs pravastatin Health‐related quality of life ‐ not reported · patients with hypercholesterolemia Chinese herbal medicines for hypercholesterolemia (2011) · Cochrane | no estimate extracted | NR | No studies |
Xuezhikang vs pravastatin Serious adverse events · patients with hypercholesterolemia Chinese herbal medicines for hypercholesterolemia (2011) · Cochrane | no estimate extracted | 0 studies · 312 participants | Ungraded |
Xuezhikang vs pravastatin Health costs · patients with hypercholesterolemia Chinese herbal medicines for hypercholesterolemia (2011) · Cochrane | no estimate extracted | NR | No studies |
Xuezhikang vs pravastatin LDL‐cholesterol · patients with hypercholesterolemia Chinese herbal medicines for hypercholesterolemia (2011) · Cochrane | no estimate extracted | 3 studies · 307 participants | Low |
Xuezhikang vs pravastatin HDL‐cholesterol · patients with hypercholesterolemia Chinese herbal medicines for hypercholesterolemia (2011) · Cochrane | no estimate extracted | 3 studies · 307 participants | Low |
Xuezhikang vs simvastatin Death from any cause ‐ not reported · patients with hypercholesterolemia Chinese herbal medicines for hypercholesterolemia (2011) · Cochrane | no estimate extracted | NR | No studies |
Xuezhikang vs simvastatin Health‐related quality of life ‐ not reported · patients with hypercholesterolemia Chinese herbal medicines for hypercholesterolemia (2011) · Cochrane | no estimate extracted | NR | No studies |
Xuezhikang vs simvastatin Serious adverse events · patients with hypercholesterolemia Chinese herbal medicines for hypercholesterolemia (2011) · Cochrane | no estimate extracted | 0 studies · 703 participants | Ungraded |
Xuezhikang vs simvastatin Health costs ‐ not reported · patients with hypercholesterolemia Chinese herbal medicines for hypercholesterolemia (2011) · Cochrane | no estimate extracted | NR | No studies |
Xuezhikang vs simvastatin LDL‐cholesterol · patients with hypercholesterolemia Chinese herbal medicines for hypercholesterolemia (2011) · Cochrane | no estimate extracted | 10 studies · 885 participants | Very low |
Xuezhikang vs simvastatin HDL‐cholesterol · patients with hypercholesterolemia Chinese herbal medicines for hypercholesterolemia (2011) · Cochrane | no estimate extracted | 9 studies · 805 participants | Very low |
Xuezhikang vs pravastatin Cardiovascular events ‐ not reported · patients with hypercholesterolemia Chinese herbal medicines for hypercholesterolemia (2011) · Cochrane | no estimate extracted | NR | No studies |
Xuezhikang vs pravastatin Death from any cause ‐ not reported · patients with hypercholesterolemia Chinese herbal medicines for hypercholesterolemia (2011) · Cochrane | no estimate extracted | NR | No studies |
Statins plus beta interferon vs beta interferon Number of participants with relapses at 12 months Number of participants with relapses at 12 months · multiple sclerosis Statins for multiple sclerosis (2011) · Cochrane | RR 1 [0.45, 2.23] | 1 study · 34 participants | Very low |
Statins plus beta interferon vs beta interferon Number of participants with relapses at 24 months Number of participants with relapses at 24 months · multiple sclerosis Statins for multiple sclerosis (2011) · Cochrane | RR 0.7 [0.36, 1.36] | 1 study · 45 participants | Very low |
Statins plus beta interferon vs beta interferon Number of participants with progression at 12 months3 ‐ not reported · multiple sclerosis Statins for multiple sclerosis (2011) · Cochrane | no estimate extracted | NR | No studies |
Statins plus beta interferon vs beta interferon Number of participants with progression at 24 months Number of participants with progression at 24 months · multiple sclerosis Statins for multiple sclerosis (2011) · Cochrane | RR 0.13 [0.01, 2.22] | 1 study · 45 participants | Very low |
Statins plus beta interferon vs beta interferon Number of participants with new T2 or GELs at 12 months Number of participants with new T2 or GELs at 12 months · multiple sclerosis Statins for multiple sclerosis (2011) · Cochrane | RR 1 [0.3, 3.36] | 1 study · 34 participants | Very low |
Statins plus beta interferon vs beta interferon Number of participants with new T2 or GELs at 24 months3 ‐ not reported · multiple sclerosis Statins for multiple sclerosis (2011) · Cochrane | no estimate extracted | NR | No studies |
Statins plus beta interferon vs beta interferon Changes of EDSS at 12 months Changes of EDSS at 12 months · multiple sclerosis Statins for multiple sclerosis (2011) · Cochrane | no estimate extracted | 2 studies · 387 participants | Moderate |
Education vs control Exacerbations leading to emergency department visits · children with asthma Home‐based educational interventions for children with asthma (2011) · Cochrane | no estimate extracted | 8 studies · 985 participants | Very low |
Education vs control Mean exacerbations requiring a course of oral corticosteroids · children with asthma Home‐based educational interventions for children with asthma (2011) · Cochrane | no estimate extracted | 2 studies · 500 participants | Very low |
Education vs other home‐based education Exacerbations leading to ED visits · patients with children with asthma Home‐based educational interventions for children with asthma (2011) · Cochrane | no estimate extracted | 1 study · 181 participants | Very low |
Education vs other home‐based education Mean exacerbations requiring a course of oral corticosteroids · patients with children with asthma Home‐based educational interventions for children with asthma (2011) · Cochrane | no estimate extracted | 1 study · 193 participants | Very low |
GM‐CSF vs placebo Induction of clinical remission (CDAI < or = 150) · patients with induction of remission in Crohn's disease Sargramostim (GM‐CSF) for induction of remission in Crohn's disease (2011) · Cochrane | RR 1.67 [0.8, 3.5] | 3 studies · 537 participants | Low |
GM‐CSF vs placebo Induction of 100‐point clinical response · patients with induction of remission in Crohn's disease Sargramostim (GM‐CSF) for induction of remission in Crohn's disease (2011) · Cochrane | RR 1.71 [0.98, 2.97] | 3 studies · 537 participants | Low |
GM‐CSF vs placebo Induction of 70‐point clinical response · patients with induction of remission in Crohn's disease Sargramostim (GM‐CSF) for induction of remission in Crohn's disease (2011) · Cochrane | RR 1.23 [0.83, 1.82] | 1 study · 124 participants | Low |
GM‐CSF vs placebo Adverse events · patients with induction of remission in Crohn's disease Sargramostim (GM‐CSF) for induction of remission in Crohn's disease (2011) · Cochrane | RR 1.06 [0.99, 1.15] | 2 studies · 251 participants | Moderate |
GM‐CSF vs placebo Serious adverse events · patients with induction of remission in Crohn's disease Sargramostim (GM‐CSF) for induction of remission in Crohn's disease (2011) · Cochrane | RR 2.17 [0.82, 5.7] | 2 studies · 251 participants | Moderate |
Intervention NR How many people get cholera during the first 2 years after vaccination? · Adults and children Oral vaccines for preventing cholera (2011) · Cochrane | no estimate extracted | 4 studies · 29005 participants | High |
Intervention NR How long does the protection last? · Adults and children Oral vaccines for preventing cholera (2011) · Cochrane | no estimate extracted | 1 study · 58184 participants | Moderate |
Intervention NR Are there any side effects? · Adults and children Oral vaccines for preventing cholera (2011) · Cochrane | no estimate extracted | 14 studies · 44924 participants | Moderate |
Corticosteroids vs placebo Vertigo · Patients with idiopathic acute vestibular dysfunction (vestibular neuritis) Corticosteroids for the treatment of idiopathic acute vestibular dysfunction (vestibular neuritis) (2011) · Cochrane | RR 0.39 [0.04, 3.57] | 2 studies · 60 participants | Low |
Corticosteroids vs placebo Dizziness Handicap Inventory score · Patients with idiopathic acute vestibular dysfunction (vestibular neuritis) Corticosteroids for the treatment of idiopathic acute vestibular dysfunction (vestibular neuritis) (2011) · Cochrane | no estimate extracted | 1 study · 30 participants | Low |
Corticosteroids vs placebo Caloric extent of recovery (improvement as a % in lateralisation of electronystagmography on caloric testing) · Patients with idiopathic acute vestibular dysfunction (vestibular neuritis) Corticosteroids for the treatment of idiopathic acute vestibular dysfunction (vestibular neuritis) (2011) · Cochrane | no estimate extracted | 1 study · 30 participants | Low |